Pazopanib vs sunitinib (targeted agent versus targeted agent)
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
- HR 1.05 [0.9, 1.23]1 study · 1110 participantsLow